Copolymer-drug conjugate for treatment of tumours
AssigneeDanmarks Tekniske Universitet
InventorsAnton Allen Abbotsford Autzen, Neil Jean Borthwick
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to a copolymer-drug-conjugate. Specifically disclosed herein are copolymer-drug-conjugates having good tissue retention. Disclosed herein are also copolymer-drug-conjugates for use in medicine, such as for use in the treatment of cancers. Disclosed herein are also methods for producing such copolymer-drug-conjugates.
Claims55
A copolymer-drug-conjugate comprising an amphiphilic copolymer and 3 or more anti-cancer drug moieties conjugated to said amphiphilic copolymer.
The copolymer-drug-conjugate according to any one of the preceding claims, wherein the amphiphilic copolymer is polymerized from:
- a. styrene and/or diisobutylene, and
- b. acrylic acid, methacrylic acid, and/or maleic acid.
The copolymer-drug-conjugate according to any one of the preceding claims, wherein the amphiphilic copolymer is a poly(acrylic acid-co-styrene) copolymer, a poly(methacrylic acid-co-styrene) copolymer, a poly(maleic acid-co-styrene) copolymer, or a poly(diisobutylene-co-maleic acid) copolymer.
The copolymer-drug-conjugate according to any one of the preceding claims, wherein the anti-cancer drug moieties are conjugated to said amphiphilic copolymer via a bond or a linking group.
A copolymer-drug-conjugate having the structure of formula (III):
- wherein:
- each R1 is independently selected from CH3 and H,
- each Ry is independently selected from H, COOH, and COX-L-R2,
- each Rz is independently selected from H and CH3,
- each Rx is independently selected from
- each X is independently selected from O, S, or NH,
- each L is independently a bond or a linking group,
- each R2 is independently selected from H or an anti-cancer drug, wherein at least 3 of R2 are an anti-cancer drug moiety,
- each T is the same or different terminal groups,
- n is between 5 and 500,
- m is between 5 and 500,
- wherein the copolymer is a random, alternating, or statistical copolymer.
The copolymer-drug-conjugate according to any one of the preceding claims, wherein the copolymer-drug-conjugate has the structure of formula (I):
- wherein:
- each R1 is independently selected from CH3 and H,
- each X is independently selected from O, S, or NH,
- each L is independently a bond or a linking group,
- each R2 is independently selected from H or an anti-cancer drug, wherein at least 3 of R2 are an anti-cancer drug moiety,
- each T is the same or different terminal groups,
- n is between 5 and 500,
- m is between 5 and 500,
- wherein the copolymer is a random, alternating, or statistical copolymer.
The copolymer-drug-conjugate according to any one of the preceding claims, wherein R1 is CH3.
The copolymer-drug-conjugate according to any one of the preceding claims, wherein the copolymer set out in formula (I) is a poly(methacrylic acid-co-styrene) copolymer or a poly(acrylic acid-co-styrene) copolymer.
The copolymer-drug-conjugate according to any one of the preceding claims, wherein the copolymer-drug-conjugate has the structure of formula (II):
The copolymer-drug-conjugate according to any one of the preceding claims, wherein X is selected from O, S, or NH, such as wherein X is O.
The copolymer-drug-conjugate according to any one of the preceding claims, wherein L is a bond.
The copolymer-drug-conjugate according to any one of the preceding claims, wherein L is a linking group selected from PEG, alkylenes, triazoles, and a group form from reaction between a haloalkyl and a nucleophile.
The copolymer-drug-conjugate according to any one of the preceding claims, wherein the copolymer of the copolymer-drug-conjugate has a molecular mass of less than 20 kDa, such as less than 15 kDa, such as less than 14 kDa, such as less than 13 kDa, and/or wherein the copolymer has a molecular mass of at least 1 kDa, such as at least 3 kDa, such as at least 5 kDa, such as at least 7 kDa, such as at least 9 kDa.
The copolymer-drug-conjugate according to any one of the preceding claims, wherein the anti-cancer drug is an anti-tumour drug.
The copolymer-drug-conjugate according to any one of the preceding claims, wherein the anti-tumour drug is an anti-tumour drug with effect against solid tumours.
The copolymer-drug-conjugate according to any one of the preceding claims, wherein the anti-cancer drug is a Toll-Like Receptor (TLR) agonist, such as a TLR7 agonist, a TLR8 agonist, or a TLR7/8 agonist.
The copolymer-drug-conjugate according to any one of the preceding claims, wherein the anti-cancer drug has the structure of formula (A-I), formula (A-II), formula (A-III), or formula (A-IV):
- wherein
- X1a is —O—, —S—, or —NRCa;
- R1a is hydrogen, (C1-10)alkyl, substituted (C1-10)alkyl, C6-10aryl, or substituted C6-10aryl, C5-9heterocyclic, substituted C5-9heterocyclic;
- RCa is hydrogen, (C1-10)alkyl, or substituted C1-10alkyl;
- or RCa and R1a taken together with the nitrogen atom to which they are attached form a heterocyclic ring or a substituted heterocyclic ring;
- each R2a is independently —OH, (C1-C6)alkyl, substituted (C1-C6)alkyl, (C1-C6)alkoxy, substituted (C1-C6)alkoxy, —C(O)—(C1-C6)alkyl (alkanoyl), substituted-C(O)—(C1-C6)alkyl, —C(O)—(C6-C10) aryl (aroyl), substituted-C(O)—(C6-C10) aryl, —C(O)OH (carboxyl), —C(O)O(C1-C6)alkyl (alkoxycarbonyl), substituted-C(O)O(C1-C6)alkyl, —NRaaRba, —C(O) NRaaRba (carbamoyl), halo, nitro, or cyano, or R2a is absent;
- each Raa and Rba is independently hydrogen, (C1-C6)alkyl, substituted (C1-C6)alkyl, (C3-C5) cycloalkyl, substituted (C3-C8) cycloalkyl, (C1-C6)alkoxy, substituted (C1-C6)alkoxy, (C1-C6)alkanoyl, substituted (C1-C6)alkanoyl, aryl, aryl(C1-C6)alkyl, Het, Het (C1-C6)alkyl, or (C1-C6)alkoxycarbonyl;
- wherein the substituents on any alkyl, aryl or heterocyclic groups are hydroxy, C1-6alkyl, hydroxyC1-6alkylene, C1-6alkoxy, C3-6cycloalkyl, C1-6alkoxy C1-6alkylene, amino, cyano, halo, or aryl;
- j is 0, 1, 2, 3 or 4;
- X3a is —N— or —CH—;
- R4a is —CH2— or —CH(R2a)—;
- k is 0 or 1;
- X4a is —O—, —S—, —NH—, —N(Rda)—, —CH2—, or —CH(R2a)—;
- each Rda is independently —OH, (C1-C6)alkyl, substituted (C1-C5)alkyl, (C1-C6)alkoxy, substituted (C1-C6)alkoxy, —C(O)—(C1-C6)alkyl (alkanoyl), substituted-C(O)—(C1-C6)alkyl, —C(O)—(C6-C10) aryl (aroyl), substituted-C(O)—(C6-C10) aryl, —C(O)O(C1-C6)alkyl (alkoxycarbonyl), substituted-C(O)O(C1-C6)alkyl, —C(O) NRaaRba (carbamoyl);
- or a tautomer thereof.
The copolymer-drug-conjugate according to any one of the preceding claims, wherein the anti-cancer drug has the structure of formula (B-I):
- wherein
- R1b represents (C1-8)alkyl, (C3-8) cycloalkyl, or a 3- to 8-membered saturated heterocyclic ring group comprising a O atom, wherein R1b is optionally substituted by one or more substituents independently selected from halogen, cyano, hydroxyl and (C1-3)alkoxy;
- Z1b represents a (C2-6)alkylene group, wherein a carbon atom in Z1b which is not adjacent to a nitrogen atom may be replaced with an oxygen atom;
- X1b represents NR5b, >N—COR5b, >N—CONR5bR5ab, CONR5b, NR5bCO, NR5bCONR6b or NR6bCONR5b;
- Y1b represents a single bond or (C1-6)alkylene;
- each R2b is independently selected from halogen, cyano, hydroxy, thiol, (C1-3)alkyl, (C1-3) hydroxyalkyl, (C1-3)haloalkyl, (C1-3)alkoxy, (C1-3)haloalkoxy, (C1-3)alkylthio, (C1-3)alkylsulfonyl and (C1-3)alkylsulfinyl;
- R3b represents C1-6 alkyl optionally substituted by (C1-6)alkoxy;
- each Rab is independently selected from halogen, cyano, hydroxy, thiol, (C1-3)alkyl, (C1-3) hydroxyalkyl, (C1-3)haloalkyl, (C1-3)alkoxy, (C1-3)haloalkoxy, (C1-3)alkylthio, (C1-3)alkylsulfonyl and (C1-3)alkylsulfinyl;
- R5b and R5ab each independently represents hydrogen, a 3- to 8-membered saturated heterocyclic ring comprising a ring group O, S(O)p or NR10b, a (C1-6)alkyl group or (C3-6) cycloalkyl group, the latter two groups being optionally substituted by one or more substituents independently selected from NR7bR8b or R9b, R7b and R8b each independently represent hydrogen, a 3- to 8-membered saturated heterocyclic ring comprising a ring group O, S(O)p or NR10ab, (C1-6)alkyl or (C3-6) cycloalkyl, the latter two groups being optionally substituted by one or more groups independently selected from halogen, cyano, S(O)qR11b, OR12b, CO2R12b, OC(O)R12b, SO2NR12bR13b CONR12bR13b, NR12bR13b, NR12bSO2R14b, NR12bCOR13b, or a 3- to 8-membered saturated heterocyclic ring comprising a ring group O, S(O)p or NR10bb,
- or R7b and R8b together with the nitrogen atom to which they are attached form a 3- to 8-membered saturated heterocyclic ring comprising a ring nitrogen atom and optionally one or more further heteroatoms independently selected from nitrogen, oxygen, sulphur and sulphonyl, the heterocyclic ring being optionally substituted by one or more substituents independently selected from halogen, cyano, S(O)qR15b, OR15b, CO2R15b, COR15b, OC(O) R15b, SO2NR15bR16b, CONR15bR16b, NR15bR16b, NR15bSO2R17b, NR15bCOR16b, NR15bCO2R16b, heteroaryl, (C1-6)haloalkyl, (C3-8) cycloalkyl and (C1-6)alkyl, the latter two groups being optionally substituted by one or more groups independently selected from cyano, S(O)qR18b, OR18b, CO2R18b, SO2NR18bR19b, CONR18bR19b or NR18bR19b;
- ROb represents halogen, cyano, CO2R20b, S(O)qR20b, OR20b, SO2NR20bR22b, CONR20bR22b, NR20bSO2R21b, NR20bCO2R21b, NR20bCOR22b or a 3- to 8-membered saturated heterocyclic ring comprising a ring group NR10cb;
- R10b, R10ab, R10bb and R10cb independently represent hydrogen, CO2R23b, S(O)qR23b, COR24b, or a (C1-6)alkyl, (C2-6)alkenyl, (C2-6)alkynyl or (C3-8) cycloalkyl group, each of which may be optionally substituted by one or more substituents independently selected from halogen, cyano, OR25b or NR25bR26b;
- R6b, R11b, R12b, R13b, R15b, R16b, R18b, R19b, R20b, R22b, R24b, R25b and R26b each independently represent hydrogen, (C1-6)alkyl or (C3-6) cycloalkyl;
- R14b, R17b, R21b and R23b each independently represent (C1-6)alkyl or (C3-6)cycloalkyl;
- h, i, p and q each independently represent an integer 0, 1 or 2;
- and
- Ab represents a monocyclic or bicyclic (C6-10) aryl or a monocyclic or bicyclic (C5-12) heteroaryl group containing 1-3 heteroatoms;
- and
- Rbb and Rcb independently represent hydrogen or (C1-6)alkyl, or Rbb and Rcb combine together to form (C3-8) cycloalkyl.
The copolymer-drug-conjugate according to any one of the preceding claims, wherein the anti-cancer drug has the structure of formula (C-I):
- wherein
- R1c is selected from the group consisting of —(C2-6)alkyl-N(R3c)2, —(C2-6)alkyl-NR3c—SO2—Xc—R4c, and —(C2-6)alkyl-NR6c—SO2—R7c;
- Xc is a bond or —NR5c—;
- R4c is alkyl, aryl, or heteroaryl;
- R2c is selected from the group consisting of hydrogen, alkyl, alkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, alkyl-O-aryl, alkyl-O-alkyl, alkyl-O-alkenyl, and alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:
- OH, halogen, —N(R3c)2, —CO—N(R3c)2, —CO—(C1-10)alkyl, —CO—O—(C1-10)alkyl, —N3, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclyl, substituted heterocyclyl, —CO-aryl, —CO-(substituted aryl), —CO-heteroaryl, and —CO-(substituted heteroaryl);
- each R3c is independently selected from the group consisting of hydrogen and (C1-10)alkyl,
- R5c is selected from the group consisting of hydrogen and (C1-10)alkyl, or R4c and R5c can combine to form a 3 to 7 membered heterocyclic or substituted heterocyclic ring;
- R6c is selected from the group consisting of hydrogen and (C1-10)alkyl;
- R7c is selected from the group consisting of hydrogen and (C1-10)alkyl, or R5c and R7c can combine to form a 3 to 7 membered heterocyclic or substituted heterocyclic ring;
- r is 0 to 4 and each Rc present is independently selected from the group consisting of (C1-10)alkyl, (C1-10)alkoxy, halogen and trifluoromethyl.
The copolymer-drug-conjugate according to any one of the preceding claims, wherein the TLR7, the TLR8, or the TLR7/8 agonist is selected from the list consisting of:
- Imiquimod, Resiquimod, Gardiquimod, 852A, Loxoribine, Bropirimine, 3M-011 (CAS no. 642473-62-9), 3M-052 (CAS no. 1359993-59-1), DSR-6434 (CAS no. 1059070-10-8), DSR-29133, SZU-101, SM-360320 (CAS no. 226907-52-4), SM-276001 (CAS no. 473930-22-2), VTX-2337 (CAS no. 926927-61-9), and 1-(3-aminopropyl)-2-(ethoxymethyl) imidazo[4,5-c]quinolin-4-amine.
The copolymer-drug-conjugate according to any one of the preceding claims, wherein the anti-cancer drug is a Stimulator of Interferon Genes (STING) agonist.
The copolymer-drug-conjugate according to any one of the preceding claims, wherein the anti-cancer drug is IL-2, IL-12, or IL-15, or a fragment thereof.
The copolymer-drug-conjugate according to any one of the preceding claims, wherein the anti-cancer drug is a radiopharmaceutical drug or a radioactive agent.
The copolymer-drug-conjugate according to any one of the preceding claims, wherein the copolymer-drug-conjugate comprises one type of anti-cancer drug.
The copolymer-drug-conjugate according to any one of the preceding claims, wherein the copolymer-drug-conjugate comprises two or more different anti-cancer drugs.
The copolymer according to any one of the preceding claims, wherein L is a linking group and wherein the moiety R2 is conjugated to L at a carbon atom or a heteroatom such as N, O, or S in R2.
The copolymer according to any one of the preceding claims, wherein L is a bond and wherein the moiety R2 is conjugated to X at a carbon atom or a heteroatom such as N, O, or S in R2.
The copolymer-drug-conjugate according to any one of the preceding claims, wherein T is independently selected from the group consisting of H, alkyl, substituted alkyl, nitrile, hydroxy, carboxyl, halogen, thiol, substituted thiol, acyl, substituted acyl, a group of formula X-I, a group of formula Y-I, a group of formula Y-II, a fluorescent dye, a diagnostic agent;
- wherein the group of formula X-I has the structure:
- wherein R3 and R4 are each independently selected from hydrogen, alkyl, and substituted alkyl;
- wherein the group of formula Y-I has the structure:
- wherein R5 is selected from hydrogen, alkyl, and substituted alkyl;
- and
- wherein the group of formula Y-II has the structure:
- wherein R5 is selected from hydrogen, alkyl, and substituted alkyl, and
- X2 and X3 are each independently selected from S and O.
The copolymer-drug-conjugate according to any one of the preceding claims, wherein the fluorescent dye is selected from the group consisting of a cyanine dye such as indocyanine green or cyanine 7, a triarylmethane dye such as fluorescein, a thiazine dye such as methylene blue, LUM015, VGT-309, AVB-620, C-Dots, BLZ-100.
A pharmaceutical composition comprising the copolymer-drug-conjugate according to any one of the preceding claims.
A method for synthesising the copolymer-drug-conjugate according to any one of the preceding claims, said method comprising conjugating an anti-cancer drug to a precursor copolymer, such as a precursor poly(methacrylic acid-co-styrene) copolymer, a precursor poly(acrylic acid-co-styrene) copolymer, a precursor poly(maleic acid-co-styrene) copolymer, or a precursor poly(diisobutylene-co-maleic acid) copolymer.
Use of a copolymer polymerized from:
- a. styrene and/or diisobutylene, and
- b. acrylic acid, methacrylic acid, and/or maleic acid
- for retaining an agent within a tissue.
A method of increasing the residence time of an agent in a tissue such as a cancer tissue, said method comprising administering the agent together with a copolymer polymerized from:
- a. styrene and/or diisobutylene, and
- b. acrylic acid, methacrylic acid, and/or maleic acid.
Dependencies are inferred from the claim text.